Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Longeveron ( (LGVN) ) is now available.
On May 8, 2026, Longeveron reported that a Type C meeting held with the U.S. Food and Drug Administration in late March, with a written summary in late April, addressed the ongoing Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome. The FDA recognized the high unmet need in this rare, high-mortality condition but determined that the trial’s current primary endpoint, right ventricle ejection fraction, is not suitable to demonstrate efficacy.
Because an NIH-mandated interim analysis is underway and blinded, regulators said a new primary endpoint cannot be finalized while the study is still in progress and therefore no longer classify ELPIS II as a pivotal trial. However, the FDA indicated that objective outcomes such as all-cause mortality, transplant-free survival and major adverse cardiac events will be informative, and Longeveron is capturing these measures as it prepares a revised statistical analysis plan and seeks to keep open a potential path to a future biologics license application after top-line data expected in August 2026.
The most recent analyst rating on (LGVN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and cash burn with elevated dilution/financing risk). Technicals are supportive with price above key moving averages and positive MACD, while valuation is constrained by negative earnings and no dividend. Earnings call adds medium support due to defined clinical catalysts and improved runway, tempered by declining revenue and rising expenses.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron Inc. is a Miami-based, clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and aging-related conditions. Its lead investigational product, laromestrocel (Lomecel-B), is an allogeneic mesenchymal stem cell therapy targeting hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty, and has received multiple FDA designations across these indications.
The company focuses on leveraging pro-vascular, pro-regenerative and anti-inflammatory mechanisms to address high unmet medical needs in rare pediatric and neurodegenerative diseases, positioning itself within the emerging cell therapy segment. Its HLHS program benefits from Orphan Drug, Fast Track and Rare Pediatric Disease designations, highlighting potential regulatory and market advantages if the therapy ultimately secures approval, including access to a Priority Review Voucher.
Average Trading Volume: 5,565,510
Technical Sentiment Signal: Sell
Current Market Cap: $19.82M
Find detailed analytics on LGVN stock on TipRanks’ Stock Analysis page.